Pernix Ireland Pain Limited  
C/O Pernix Therapeutics  
10 North Park Place, Suite # 201  
Morristown, NJ 07960

Attention: Blanche Reynolds  
Regulatory Project Manager

Dear Ms. Reynolds:

Please refer to your following Supplemental New Drug Applications (sNDAs) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ZOHYDRO ER (hydrocodone bitartrate) Extended-Release Capsules.

<table>
<thead>
<tr>
<th>Supplement Number</th>
<th>Submission Date</th>
<th>Receipt Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-009</td>
<td>April 21, 2016</td>
<td>April 21, 2016</td>
</tr>
<tr>
<td>S-010</td>
<td>January 26, 2016</td>
<td>February 29, 2016</td>
</tr>
</tbody>
</table>

We also refer to our letter dated March 22, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for ZOHYDRO ER. This information pertains to the risks of serotonin syndrome with concomitant use of serotonergic drugs; adrenal insufficiency; and androgen deficiency.

Additionally, we refer to our letter dated August 31, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for ZOHYDRO ER. This information pertains to the risks of concomitant use of opioid analgesics with benzodiazepines or other central nervous system depressants.

Supplement S-009 provides for the Safety Labeling Changes required under Section 505(o)(4) of the FDCA, consistent with our March 22 and August 31, 2016, letters, and additional revisions to the Package Insert.

Supplement S-010 proposes revisions to section 13 NONCLINICAL TOXICOLOGY of the Package Insert to include the results of the two-year bioassay in mouse and rat to evaluate the carcinogenic potential of hydrocodone. These studies were required to fulfill two of the postmarketing requirements listed in the October 25, 2013, approval letter.

Reference ID: 4028857
APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have reviewed your submissions and conclude that the following postmarketing requirements listed in the October 25, 2013, approval letter are fulfilled.
2066-4 Conduct a 2-year bioassay in the rat model to evaluate the carcinogenic potential of hydrocodone.

Final Protocol Submission: Protocol acceptable, study in progress
Study Completion: January 15, 2014
Final Report Submission: June 30, 2015

2066-5 Conduct a 2-year bioassay in the mouse model to evaluate the carcinogenic potential of hydrocodone.

Final Protocol Submission: Protocol acceptable, study in progress
Study Completion: January 24, 2014
Final Report Submission: June 30, 2015

We remind you that there are postmarketing requirements listed in the October 25, 2013, approval letter, and the February 4, 2016, Release from Postmarketing Requirement/New Postmarketing Requirement letter, that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug
Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mark Liberatore, PharmD; Safety Regulatory Project Manager, at (301) 796-2221.

Sincerely,

{See appended electronic signature page}

Sharon Hertz, MD
Director
Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHARON H HERTZ
12/16/2016